 |
7 Diseases |  |
1 Trial |
|
1 Trial |  |
14 News |  |
- | alteminostat (CKD-581) / Chong Kun Dang
Journal, IO biomarker: CKD-581 Downregulates Wnt/β-Catenin Pathway by DACT3 Induction in Hematologic Malignancy. (Pubmed Central) - Jul 9, 2022
Overall, CKD-581 shows anticancer activity via inhibition of the Wnt/β-catenin signaling pathway in hematologic malignancies. This finding is evidence of the therapeutic potential and rationale of CKD-581 for treatment of MM.
- | alteminostat (CKD-581) / Chong Kun Dang, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal, PARP Biomarker, IO biomarker: Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma. (Pubmed Central) - Feb 13, 2021
In a DLBCL SCID mouse xenograft model, CKD-581 exhibited anti-cancer effects comparable with those of rituximab (CD20 mAb). Our findings suggest that CKD-581 could be a good candidate for the treatment of DLBCL.
- | alteminostat (CKD-581) / Chong Kun Dang
Trial completion date, Trial primary completion date, Combination therapy: CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Feb 24, 2020
P1, N=18, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
Our findings suggest that CKD-581 could be a good candidate for the treatment of DLBCL. Trial completion date: Nov 2019 --> Sep 2021 | Trial primary completion date: Jun 2018 --> Jun 2020
- | alteminostat (CKD-581) / Chong Kun Dang
Trial completion date, Trial primary completion date, Combination therapy: CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Feb 7, 2020
P1, N=18, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
Trial completion date: Nov 2019 --> Sep 2021 | Trial primary completion date: Jun 2018 --> Jun 2020 Trial completion date: Jun 2021 --> Nov 2022 | Trial primary completion date: Jun 2019 --> Apr 2021
- dexamethasone / Generic mfg., Revlimid (lenalidomide) / BMS, CKD-581 / Chong Kun Dang
A Phase 1, Open-Label, Multi-Center Study of Alteminostat (CKD-581) in Combination with Lenalidomide and Dexamethasone in Patients with Previously Treated Multiple Myeloma (MM) (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_2692;
Conclusions Alteminostat, a novel hydroxamate-based pan-HDAC inhibitor, can be combined safely with lenalidomide and dexamethasone, demonstrating significant clinical activity in subjects with MM. Enrollment is ongoing and full phase 1 will be updated and presented.
- | CKD-581 / Chong Kun Dang
Clinical, P1 data, Journal: Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. (Pubmed Central) - Jun 5, 2019
Conclusion CKD-581 was well tolerated by the patients with lymphoma or MM refractory to standard therapy. It exhibited dose-proportional pharmacokinetics and modest anti-tumor efficacy.
- | alteminostat (CKD-581) / Chong Kun Dang
Trial completion date, Trial primary completion date, Combination therapy: CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Jul 26, 2018
P1, N=18, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
It exhibited dose-proportional pharmacokinetics and modest anti-tumor efficacy. Trial completion date: Aug 2019 --> Jun 2021 | Trial primary completion date: Jan 2018 --> Jun 2019
- | alteminostat (CKD-581) / Chong Kun Dang
New P1 trial, Combination therapy: CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - May 11, 2017
P1, N=18, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- | alteminostat (CKD-581) / Chong Kun Dang
New P1 trial, Combination therapy: CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Feb 15, 2017
P1, N=18, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- alteminostat (CKD-581) / Chong Kun Dang
Trial primary completion date: Safety and Pharmacokinetic Profile of CKD-581 (clinicaltrials.gov) - Oct 11, 2016
P1, N=39, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Trial completion date: Aug 2019 --> Jun 2021 | Trial primary completion date: Jan 2018 --> Jun 2019 Trial primary completion date: Jun 2016 --> Mar 2016
- | alteminostat (CKD-581) / Chong Kun Dang
Trial completion: Safety and Pharmacokinetic Profile of CKD-581 (clinicaltrials.gov) - Oct 5, 2016
P1, N=39, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Trial primary completion date: Jun 2016 --> Mar 2016 Recruiting --> Completed
- alteminostat (CKD-581) / Chong Kun Dang
Enrollment open, Enrollment change, Trial initiation date, Trial primary completion date: Safety and Pharmacokinetic Profile of CKD-581 (clinicaltrials.gov) - Aug 12, 2015
P1, N=40, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
Recruiting --> Completed Active, not recruiting --> Recruiting | N=24 --> 40 | Initiation date: Dec 2011 --> May 2012 | Trial primary completion date: May 2012 --> Jun 2016
- | alteminostat (CKD-581) / Chong Kun Dang
New P1 trial: Safety and Pharmacokinetic Profile of CKD-581 (clinicaltrials.gov) - Apr 15, 2012
P1, N=24, Active, not recruiting, Sponsor: Chong Kun Dang Pharmaceutical